Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 13/20 | 0.52 |
| ▸ | PARP6 | Q2NL67 | 3/20 | 0.48 |
| ▸ | PARP3 | Q9Y6F1 | 3/20 | 0.48 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22912763 | 1.00 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TIPARP | |
| Hydrochloric Acid SCHEMBL28702467 | 0.98 | PARP1 (0.51) | PARP1PARP2PARP6PARP3TIPARP | |
| Hydrochloric Acid SCHEMBL29394287 | 0.98 | PARP1 (0.51) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL25093486 | 0.89 | PARP1 (0.55) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL22912682 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL29396473 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL29394532 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL22912684 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL25606984 | 0.85 | PARP1 (0.52) | PARP1PARP2PARP6PARP3TIPARP | |
| SCHEMBL30663279 | 0.83 | ATAD2 (0.50) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025011494-A1 | CRYSTAL FORM OF PIPERAZINO RING-CONTAINING DERIVATIVE, SALT FORM, PREPARATION METHOD, AND USE | 优领医药科技(香港)有限公司 | 2025-01-16 | — | — | WO | claimed |
| CN-116348115-B | Combination of antibody-drug conjugate and PARP1 selective inhibitor | ASTRAZENECA UK LTD. (GB) | 2026-05-26 | — | — | CN | disclosed |
| EP-4606802-A1 | SALT AND CRYSTAL FORM OF HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| CN-116194110-B | Combination therapy for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-120081844-A | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-120058698-A | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120035592-A | Heterocyclyl deuterated compounds and uses thereof | 成都赜灵生物医药科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-120019055-A | Salt and crystal form of heterocyclic derivative inhibitor, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-120019054-A | Substituted tetrahydropyridines and use thereof | 成都赜灵生物医药科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-118804916-B | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-115919859-A | Pharmaceutical composition of heteroaryl derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-04-07 | — | — | CN | disclosed |
| WO-2023056039-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023046158-A1 | AZAQUINOLINONE COMPOUND AND MEDICAL USE THEREOF | 张文燕 | 2023-03-30 | — | — | WO | disclosed |
| WO-2022235585-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022228387-A1 | COMPOUNDS AS PARP INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022225934-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| CN-115232154-A | Heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-3999506-A1 | PARP1 INHIBITORS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| WO-2022074124-A1 | COMBINATION THERAPY FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2022-04-14 | — | — | WO | disclosed |
| CN-114144413-A | PARP1 inhibitors | 阿斯利康(瑞典)有限公司 | 2022-03-04 | — | — | CN | disclosed |